J. A. Ajani, J. Faust, K. Ikeda, J. C. Yao, H. Anbe et al., Phase I Pharmacokinetic Study of S-1 Plus Cisplatin in Patients With Advanced Gastric Carcinoma, Journal of Clinical Oncology, vol.23, issue.28, pp.6957-6965, 2005.
DOI : 10.1200/JCO.2005.01.917

J. Arrowsmith, Trial watch: phase iii and submission failures, Nature Reviews Drug Discovery, vol.10, pp.2007-2010, 2011.
DOI : 10.1038/nrd3375

J. Babb, A. Rogatko, and S. Zacks, Cancer phase I clinical trials: efficient dose escalation with overdose control, Statistics in Medicine, vol.17, issue.10, pp.1103-1120, 1998.
DOI : 10.1002/(SICI)1097-0258(19980530)17:10<1103::AID-SIM793>3.0.CO;2-9

B. Bornkamp, F. Bretz, A. Dmitrienko, G. Enas, B. Gaydos et al., Innovative Approaches for Designing and Analyzing Adaptive Dose-Ranging Trials, Journal of Biopharmaceutical Statistics, vol.40, issue.6, pp.965-995, 2007.
DOI : 10.2307/2530666

F. Bretz, J. C. Pinheiro, and M. Branson, Combining Multiple Comparisons and Modeling Techniques in Dose-Response Studies, Biometrics, vol.99, issue.3, pp.738-748, 2005.
DOI : 10.1016/S0378-3758(01)00077-5
URL : http://www.meduniwien.ac.at/wbs/2006_13_Maerz_Bretz.pdf

L. E. Broker, F. Y. De-vos, C. J. Van-groeningen, B. C. Kuenen, H. E. Gall et al., Phase I Trial with BMS-275183, a Novel Oral Taxane with Promising Antitumor Activity, Clinical Cancer Research, vol.12, issue.6, pp.1760-1767, 2006.
DOI : 10.1158/1078-0432.CCR-05-2093
URL : http://clincancerres.aacrjournals.org/content/clincanres/12/6/1760.full.pdf

L. Bueno, D. P. De-alwis, C. Pitou, J. Yingling, M. Lahn et al., Semi-mechanistic modelling of the tumour growth inhibitory effects of LY2157299, a new type I receptor TGF-?? kinase antagonist, in mice, European Journal of Cancer, vol.44, issue.1, pp.142-150, 2008.
DOI : 10.1016/j.ejca.2007.10.008

S. Chevret, Statistical Methods for Dose-finding Experiments of Statistics in Practice, 2006.

J. M. Collins, C. K. Grieshaber, and B. A. Chabner, Pharmacologically Guided Phase I Clinical Trials Based Upon Preclinical Drug Development, JNCI Journal of the National Cancer Institute, vol.82, issue.16, pp.1321-1326, 1990.
DOI : 10.1093/jnci/82.16.1321

E. Comets and S. Zohar, A Survey of the Way Pharmacokinetics are Reported in Published Phase I Clinical Trials, with an Emphasis on Oncology, Clinical Pharmacokinetics, vol.14, issue.3, pp.387-395, 2009.
DOI : 10.1007/BF03190058
URL : https://hal.archives-ouvertes.fr/inserm-00409057

H. Derendorf, L. J. Lesko, P. Chaikin, W. A. Colburn, P. Lee et al., Pharmacokinetic/pharmacodynamic modeling in drug research and development, The Journal of Clinical Pharmacology, vol.40, pp.1399-1418, 2000.

I. Gueorguieva, A. L. Cleverly, A. Stauber, N. S. Pillay, J. A. Rodon et al., Defining a therapeutic window for the novel TGF-?? inhibitor LY2157299 monohydrate based on a pharmacokinetic/pharmacodynamic model, British Journal of Clinical Pharmacology, vol.3, issue.Suppl., pp.796-807, 2014.
DOI : 10.1007/0-306-48523-0_13

J. ¨-onsson, S. Henningsson, A. Edholm, M. Salmonson, and T. , Role of Modelling and Simulation, Clinical Pharmacokinetics, vol.64, issue.3, pp.69-76, 2012.
DOI : 10.1111/j.1365-2125.2007.02887.x

L. Tourneau, C. Lee, J. J. Siu, and L. L. , Dose Escalation Methods in Phase I Cancer Clinical Trials, JNCI: Journal of the National Cancer Institute, vol.24, issue.25, pp.708-720, 2009.
DOI : 10.1200/JCO.2006.07.4658

L. Lesko, Paving the Critical Path: How can Clinical Pharmacology Help Achieve the Vision?, Clinical Pharmacology & Therapeutics, vol.41, issue.2, pp.170-177, 2007.
DOI : 10.1038/sj.clpt.6100045

G. Lestini, C. Dumont, and F. Mentré, Influence of the Size of Cohorts in Adaptive Design for Nonlinear Mixed Effects Models: An Evaluation by Simulation for a Pharmacokinetic and Pharmacodynamic Model for a Biomarker in Oncology, Pharmaceutical Research, vol.11, issue.6, pp.3159-3169, 2015.
DOI : 10.1002/pst.1542
URL : https://hal.archives-ouvertes.fr/inserm-01179444

D. Mould and R. Upton, Basic Concepts in Population Modeling, Simulation, and Model-Based Drug Development, CPT: Pharmacometrics and Systems Pharmacology 1, p.6, 2012.
DOI : 10.1007/s10928-005-0062-y

O. Quigley, J. Hughes, M. D. Fenton, T. , P. et al., Dynamic calibration of pharmacokinetic parameters in dose-finding studies, Biostatistics, vol.80, issue.2, pp.537-545, 2010.
DOI : 10.1080/01621459.1985.10478213

O. Quigley, J. Pepe, M. Fisher, and L. , Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer, Biometrics, vol.46, issue.1, pp.33-48, 1990.
DOI : 10.2307/2531628

S. Patterson, S. Francis, M. Ireson, D. Webber, and J. Whitehead, A NOVEL BAYESIAN DECISION PROCEDURE FOR EARLY-PHASE DOSE-FINDING STUDIES, Journal of Biopharmaceutical Statistics, vol.91, issue.4, pp.583-597, 1999.
DOI : 10.2307/2291752

S. Piantadosi and G. Liu, IMPROVED DESIGNS FOR DOSE ESCALATION STUDIES USING PHARMACOKINETIC MEASUREMENTS, Statistics in Medicine, vol.15, issue.15, pp.1605-1618, 1996.
DOI : 10.1002/(SICI)1097-0258(19960815)15:15<1605::AID-SIM325>3.0.CO;2-2

W. F. Rosenberger and L. M. Haines, Competing designs for phase I clinical trials: a review, Statistics in Medicine, vol.9, issue.18, pp.2757-2770, 2002.
DOI : 10.1081/BIP-100100998

J. Whitehead and H. Brunier, BAYESIAN DECISION PROCEDURES FOR DOSE DETERMINING EXPERIMENTS, Statistics in Medicine, vol.32, issue.9, pp.885-893, 1995.
DOI : 10.1002/sim.4780140904

J. Whitehead, S. Patterson, D. Webber, S. Francis, and Y. Zhou, Easy-to-implement Bayesian methods for dose-escalation studies in healthy volunteers, Biostatistics, vol.2, issue.1, pp.47-61, 2001.
DOI : 10.1093/biostatistics/2.1.47

J. Whitehead, Y. Zhou, L. Hampson, E. Ledent, and A. Pereira, A Bayesian Approach for Dose-Escalation in a Phase I Clinical Trial Incorporating Pharmacodynamic Endpoints, Journal of Biopharmaceutical Statistics, vol.37, issue.6, pp.1117-1129, 2007.
DOI : 10.1002/pst.222